abbvie glp-1 receptor agonist GLP−1 agonists for the treatment of obesity: Role as a promising approach PDB-101: Molecule of the Month:

Superfoods and medical foods designed for neuropathy offer promising options that go beyond traditional drugs

On April 1, 2026, the FDA approved orforglipron (Foundayo) by Eli Lilly for adults with obesity or overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity

The copper complex gives GHK-Cu its distinctive blue colour and contributes to its research significance in dermatological and tissue engineering studies

PMID: 169 MasonJKThompsonLU

Convenient, though systemic exposure is lower than injectable